-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Lupus Nephritis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Lupus Nephritis Drug Details: Iptacopan hydrochloride (Fabhalta) is a factor B inhibitor of...
-
Product Insights
Sinusitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Sinusitis - Drugs In Development, 2023’, provides an overview of the Sinusitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Rhinosinusitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Rhinosinusitis - Drugs In Development, 2023’, provides an overview of the Rhinosinusitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rhinosinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Cytomegalovirus (HHV-5) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Cytomegalovirus (HHV-5) Infections - Drugs In Development, 2023’, provides an overview of the Cytomegalovirus (HHV-5) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drugs In Development, 2023’, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TRL-345 in Cytomegalovirus (HHV-5) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TRL-345 in Cytomegalovirus (HHV-5) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TRL-345 in Cytomegalovirus (HHV-5) Infections Drug Details: TRL-345 (CMV-345) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aspacytarabine Hydrochloride in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aspacytarabine Hydrochloride in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Aspacytarabine Hydrochloride in Myelodysplastic Syndrome Drug Details:Aspacytarabine is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Calpurbatug in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Calpurbatug in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Calpurbatug in Methicillin-Resistant Staphylococcus aureus (MRSA) InfectionsDrug Details:calpurbatug is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Calpurbatug in Gram-Positive Bacterial Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Calpurbatug in Gram-Positive Bacterial Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Calpurbatug in Gram-Positive Bacterial InfectionsDrug Details:calpurbatug is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Calpurbatug in Gram-Negative Bacterial Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Calpurbatug in Gram-Negative Bacterial Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Calpurbatug in Gram-Negative Bacterial InfectionsDrug Details:calpurbatug is under development for the treatment of...